lp-005
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 19, 2023 (NCT06294301)
Timeline
Indications
Studied for
Mechanism of action
- Complement C5INHIBITOR
C5 inhibitor
- Complement C3INHIBITOR
C3 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266155 | Phase 2 | Dec 5, 2025 | Longbio Pharma, Nanjing Medical University |
| NCT07212426 | Phase 2 | Nov 14, 2024 | Longbio Pharma |
| NCT06294301 | Phase 1 | Nov 19, 2023 | Longbio Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Longbio Pharma | For profit | 3 | 3 | 2 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1